BIOMARKER:

ER mutation

B | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

B | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Estrogen Receptor Positive Breast Cancer

HER2 Negative Breast Cancer

Breast Cancer

Hormone Receptor Positive Breast Cancer

fulvestrant

ER mutation|Estrogen Receptor Positive Breast Cancer|fulvestrant

ER mutation|Breast Cancer|fulvestrant

ER mutation|Hormone Receptor Positive Breast Cancer|fulvestrant

G1T48

ER mutation|HER2 Negative Breast Cancer|G1T48

bevacizumab

ER mutation|Estrogen Receptor Positive Breast Cancer|bevacizumab

GDC-9545

ER mutation|HER2 Negative Breast Cancer|GDC-9545

venetoclax

ER mutation|Breast Cancer|venetoclax

palbociclib + PF-05212384

ER mutation|HER2 Negative Breast Cancer|palbociclib + PF-05212384

enobosarm

ER mutation|Estrogen Receptor Positive Breast Cancer|enobosarm

SAR439859

ER mutation|HER2 Negative Breast Cancer|SAR439859

elacestrant

ER mutation|Estrogen Receptor Positive Breast Cancer|elacestrant

palbociclib

ER mutation|Estrogen Receptor Positive Breast Cancer|palbociclib

ER mutation|Breast Cancer|palbociclib

exemestane

ER mutation|Estrogen Receptor Positive Breast Cancer|exemestane

ER mutation|Hormone Receptor Positive Breast Cancer|exemestane

Aromatase inhibitor + palbociclib

ER mutation|HER2 Negative Breast Cancer|Aromatase inhibitor + palbociclib

alpelisib

ER mutation|Hormone Receptor Positive Breast Cancer|alpelisib

CDK4 inhibitor + CDK6 inhibitor

ER mutation|HER2 Negative Breast Cancer|CDK4 inhibitor + CDK6 inhibitor